HIM
COLL icon

Hillsdale Investment Management’s Collegium Pharmaceutical COLL Stock Holding History

Hillsdale Investment Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.1M Sell
184,600
-22,000
-11% -$931K 0.17% 143
2025
Q4 		$9.57M Buy
206,600
+3,600
+2% +$151K 0.26% 63
2025
Q3 		$7.1M Buy
203,000
+25,100
+14% +$873K 0.21% 118
2025
Q2 		$5.26M Buy
177,900
+44,700
+34% +$1.27M 0.19% 158
2025
Q1 		$3.98M Buy
133,200
+17,000
+15% +$520K 0.2% 113
2024
Q4 		$3.33M Buy
116,200
+1,100
+1% +$36.4K 0.17% 173
2024
Q3 		$4.45M Buy
115,100
+300
+0.3% +$10.7K 0.34% 87
2024
Q2 		$3.7M Buy
114,800
+3,300
+3% +$114K 0.29% 128
2024
Q1 		$4.33M Buy
111,500
+17,200
+18% +$602K 0.34% 97
2023
Q4 		$2.9M Sell
94,300
-200
-0.2% -$5.01K 0.24% 162
2023
Q3 		$2.11M Sell
94,500
-73,300
-44% -$1.67M 0.19% 169
2023
Q2 		$3.61M Sell
167,800
-6,600
-4% -$150K 0.33% 127
2023
Q1 		$4.18M Buy
+174,400
New +$4.62M 0.36% 102

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Hillsdale Investment Management's COLL Position: Q1 2026 in Review

Hillsdale Investment Management reduced its Collegium Pharmaceutical (COLL) stake by 11% in Q1 2026, selling an estimated $931K and leaving 184,600 shares worth $6.1M. The position accounts for 0.17% of the portfolio, ranked #143.

Hillsdale Investment Management first reported a position in COLL in Q1 2023 and has held it in 13 quarters since. The position peaked at $9.57M in Q4 2025. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Hillsdale Investment Management held 184,600 shares of Collegium Pharmaceutical worth $6.1M as of Q1 2026.
  • Hillsdale Investment Management sold 22,000 Collegium Pharmaceutical shares in Q1 2026, an estimated $931K.
  • Collegium Pharmaceutical made up 0.17% of Hillsdale Investment Management's portfolio in Q1 2026, its #143 holding.
  • Hillsdale Investment Management first reported a position in Collegium Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
  • Hillsdale Investment Management's Collegium Pharmaceutical position peaked at $9.57M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.